Navigation Links
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Date:4/22/2010

NEW YORK, LONDON and HAMILTON, Bermuda, April 22 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the initiation of a Phase I/II pediatric dose tolerance trial to test their investigational new drug XERECEPT® in pediatric patients suffering from primary, recurrent or metastatic brain tumors.

Celtic Pharma's objective for this trial is to rapidly demonstrate the tolerability to increasing doses of XERECEPT® in pediatric patients.  Upon identification of the maximum tolerated dose, the study will continue to investigate the clinical benefits of XERECEPT® in this population, particularly with regard to reduction of dexamethasone dosing requirements and concomitant clinical benefit to the patients.  Dr. Stewart Goldman, medical director of the Neuro-Oncology unit at Northwestern University's Feinberg School of Medicine and the study's Principal Investigator commented, "I am excited to be working on this very important trial.  The effects of dexamethasone dosing on these children who have brain tumors is heart wrenching and I look forward to working with Celtic Pharma in the testing of XERECEPT® in these patients."

Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma further commented, "The current standards of care and prognosis for pediatric patients with brain tumors is very poor and we believe that XERECEPT® may provide a welcome and needed treatment for these children, in whom the effects of high-dose steroids are so devastating.  We have been in close contact with leading pediatric neuro-oncologists and look forward to the completion of this trial. This study is an important el
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
4. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
7. Who Is The Next-Generation Pharmacist(TM)?
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
11. NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
... Nov. 2, 2010 Kensey Nash Corporation (Nasdaq: ... investor conferences in November.   Michael Celano, ... presentation, at the Oppenheimer 21st Annual Healthcare Conference at ... at 2:10 p.m. (ET).  To hear the live webcast ...
Cached Medicine Technology:STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... you think winning is one of the key determinants that ... with other mental bonuses ranked near the bottom of 81 ... 11 big fun factors, according to a new study. Despite ... comes to the "fun" factor, very little research had been ... elusive conceptuntil now. , The results of this study might ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... 27 Attorney General Michael,B. Mukasey will deliver the ... Ceremony and remarks on Justice,Department nationwide efforts to combat ... be held on WEDNESDAY, MAY 28, 2008., WHO: ... WHEN: WEDNESDAY, MAY 28, 2008, 1:00 P.M. ...
... Fla. Once heralded as a promising obesity treatment, ... discovered overweight patients were resistant to its effects. But ... seems to revive the hormones ability to fight fat ... The combination of leptin and a modest dose of ...
... Finer Senior Living Expected in Coming Years, SANTA ... and scenery at Varenna. Oakmont Senior Living LLC did ... that benefits from 25 years,of experience in every facet ... new continuing care residential community sets a grand,and unparalleled ...
... is not associated with a reduced risk of prostate ... 27 in the Journal of the National Cancer ... of vitamin D may reduce the risk of prostate ... have reported inconsistent results. , In a nested case-control ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... completely unexpected way that the brain repairs nerve damage, wherein ... neurons. , Astrocytes are a type of support cell in ... is to chew up damaged nerves during brain injury and ... Roger Chung and colleagues have now found that astrocytes have ...
Cached Medicine News:Health News:Combining exercise with hormone could prevent weight gain 2Health News:Combining exercise with hormone could prevent weight gain 3Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 2Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 3Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... into comfortable holder, measuring switch is ... is performed., ,Large display of ... surroundings, back light automatically turns on ... compact contour and design provide steady, ...
Medicine Products: